Pfizer Looks To Make Its Big Pharma Engine More Agile By Cutting 10,000
This article was originally published in The Pink Sheet Daily
Executive Summary
Company's reorganization will include R&D rationalization, manufacturing consolidation and European field force cuts.
You may also be interested in...
Pfizer Avoids Japan R&D Layoffs With Creation Of New Business
Company spins off part of Nagoya research site into venture-backed RaQualia Pharma.
Pfizer Avoids Japan R&D Layoffs With Creation Of New Business
Company spins off part of Nagoya research site into venture-backed RaQualia Pharma.
Pfizer Spins Off Esperion While Retaining Former Subsidiary’s Top Compounds
Pfizer retains undisclosed stake in Esperion, which will focus on small-molecule dyslipidemia candidate.